Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML

Higher-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) of the elderly exhibit several commonalities, including first line treatment with hypomethylating agents (HMA) like azacitidine (AZA) or decitabine (DAC). Until today, response to treatment occurs in less than 50 percent of...

Descripción completa

Detalles Bibliográficos
Autores principales: Kubasch, Anne Sophie, Platzbecker, Uwe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025349/
https://www.ncbi.nlm.nih.gov/pubmed/29795051
http://dx.doi.org/10.3390/cancers10060158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025349/
https://www.ncbi.nlm.nih.gov/pubmed/29795051
http://dx.doi.org/10.3390/cancers10060158

Ejemplares similares